CA2721980C - Selective high-affinity poly dentate ligands and methods of making such - Google Patents

Selective high-affinity poly dentate ligands and methods of making such Download PDF

Info

Publication number
CA2721980C
CA2721980C CA2721980A CA2721980A CA2721980C CA 2721980 C CA2721980 C CA 2721980C CA 2721980 A CA2721980 A CA 2721980A CA 2721980 A CA2721980 A CA 2721980A CA 2721980 C CA2721980 C CA 2721980C
Authority
CA
Canada
Prior art keywords
shal
ligand
linker
ligands
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2721980A
Other languages
English (en)
French (fr)
Other versions
CA2721980A1 (en
Inventor
Sally J. Denardo
Gerald L. Denardo
Rodney L. Balhorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lawrence Livermore National Security LLC
University of California San Diego UCSD
Original Assignee
Lawrence Livermore National Security LLC
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lawrence Livermore National Security LLC, University of California San Diego UCSD filed Critical Lawrence Livermore National Security LLC
Publication of CA2721980A1 publication Critical patent/CA2721980A1/en
Application granted granted Critical
Publication of CA2721980C publication Critical patent/CA2721980C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
CA2721980A 2008-04-21 2009-04-21 Selective high-affinity poly dentate ligands and methods of making such Active CA2721980C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4671208P 2008-04-21 2008-04-21
US61/046,712 2008-04-21
PCT/US2009/041276 WO2009132020A2 (en) 2008-04-21 2009-04-21 Selective high-affinity polydentate ligands and methods of making such

Publications (2)

Publication Number Publication Date
CA2721980A1 CA2721980A1 (en) 2009-10-29
CA2721980C true CA2721980C (en) 2017-01-03

Family

ID=41217391

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2721980A Active CA2721980C (en) 2008-04-21 2009-04-21 Selective high-affinity poly dentate ligands and methods of making such

Country Status (8)

Country Link
US (5) US9884070B2 (https=)
EP (1) EP2268654B1 (https=)
JP (2) JP5623384B2 (https=)
CN (1) CN102083850B (https=)
AU (1) AU2009239491B2 (https=)
CA (1) CA2721980C (https=)
ES (1) ES2613844T3 (https=)
WO (1) WO2009132020A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4497432A4 (en) * 2022-03-22 2025-07-30 Bion Inc PROTEIN DELIVERY COMPOSITION CONTAINING BILE SALT AND CATIONIC PEPTIDE AND USE THEREOF

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011057078A2 (en) 2009-11-05 2011-05-12 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
BR112014015197A8 (pt) * 2011-12-21 2017-06-13 Novira Therapeutics Inc agentes antivirais de hepatite b
JP6103832B2 (ja) * 2012-06-25 2017-03-29 Hoya株式会社 Ｅｇｆｒ結合性ペプチド
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
JP2017525678A (ja) * 2014-07-14 2017-09-07 ピーイージー バイオサイエンシーズ インコーポレイテッド 重合エンケファリンプロドラッグ
CN105985524A (zh) * 2015-02-10 2016-10-05 北京师范大学 针对特定靶标具备指纹识别特征的多肽复合物分子的构建方法
KR102646956B1 (ko) 2015-02-26 2024-03-14 소니그룹주식회사 페닐에티닐나프탈렌 염료 및 이의 사용 방법
US11827661B2 (en) 2015-02-26 2023-11-28 Sony Group Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
CN107709470B (zh) 2015-05-11 2021-01-29 索尼公司 超亮二聚或多聚染料
US10542961B2 (en) 2015-06-15 2020-01-28 The Research Foundation For The State University Of New York System and method for infrasonic cardiac monitoring
CN105678112B (zh) * 2016-02-03 2018-08-03 中国农业科学院北京畜牧兽医研究所 一种计算机辅助筛选小分子化合物靶标适配体的实现方法
CN109415574B (zh) 2016-04-01 2021-05-28 索尼公司 具有刚性间隔基团的超亮二聚体或聚合物染料
AU2017240154B2 (en) 2016-04-01 2021-08-12 Sony Group Corporation Ultra bright dimeric or polymeric dyes
WO2017177065A2 (en) 2016-04-06 2017-10-12 Sony Corporation Ultra bright dimeric or polymeric dyes with spacing linker groups
JP7527537B2 (ja) 2016-05-10 2024-08-05 ソニーグループ株式会社 ペプチド骨格を有する超明色ポリマー染料
EP3455299B1 (en) 2016-05-10 2024-01-17 Sony Group Corporation Compositions comprising a polymeric dye and a cyclodextrin and uses thereof
EP3455300A1 (en) 2016-05-11 2019-03-20 Sony Corporation Ultra bright dimeric or polymeric dyes
EP3464477A1 (en) 2016-06-06 2019-04-10 Sony Corporation Ionic polymers comprising fluorescent or colored reporter groups
JP7312929B2 (ja) 2016-07-29 2023-07-24 ソニーグループ株式会社 超明色二量体またはポリマー色素およびその調製のための方法
US11524988B2 (en) 2016-09-19 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
WO2018098384A1 (en) * 2016-11-22 2018-05-31 Regents Of The University Of California Segregation modulation for immunotherapy
WO2018152434A1 (en) * 2017-02-17 2018-08-23 The Regents Of The University Of California Systems and methods for making assignments in isotope-labelled proteins using nuclear magnetic resonance data
WO2018156735A1 (en) * 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
WO2019071153A1 (en) * 2017-10-05 2019-04-11 Sony Corporation PROGRAMMABLE DENDRITIC MEDICINES
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
WO2019089765A1 (en) * 2017-11-01 2019-05-09 Arrowhead Pharmcaceuticals, Inc. Integrin ligands and uses thereof
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
CN111565756A (zh) 2018-01-12 2020-08-21 索尼公司 包含生物活性化合物的具有刚性间隔基团的聚合物
US12539334B2 (en) 2018-01-12 2026-02-03 Sony Group Corporation Phosphoalkyl polymers comprising biologically active agents
EP3737417B1 (en) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
KR102742386B1 (ko) 2018-03-19 2024-12-16 소니그룹주식회사 형광 신호 향상을 위한 2가 금속의 사용
CN118480073A (zh) 2018-03-21 2024-08-13 索尼公司 具有连接体基团的聚合串联染料
US20210236668A1 (en) * 2018-04-03 2021-08-05 The Trustees Of Columbia University In The City Of New York Compositions for radiotherapy and uses thereof
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
KR20210032434A (ko) 2018-07-13 2021-03-24 소니 주식회사 유기인산염 단위를 포함하는 백본을 갖는 중합체성 염료
CN109283842B (zh) * 2018-08-02 2022-01-07 哈尔滨工程大学 一种无人艇航迹跟踪智能学习控制方法
WO2021062176A2 (en) 2019-09-26 2021-04-01 Sony Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
WO2021127583A1 (en) * 2019-12-20 2021-06-24 Shal Technologies, Inc. Selective high affinity ligand diagnostics and therapeutics
AU2021251875A1 (en) * 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
CN115043898B (zh) * 2021-03-08 2024-12-31 迈克生物股份有限公司 生物素化抗原衍生物及相关试剂盒和用途
CN113960317A (zh) * 2021-08-19 2022-01-21 深圳市辅酶医科技有限公司 一种测量生物样品中nad+浓度的生物传感器及方法
EP4466706A1 (en) * 2022-01-18 2024-11-27 NEC Laboratories Europe GmbH Methods of vaccine design
WO2024059858A2 (en) * 2022-09-15 2024-03-21 Ligandal, Inc. Approaches to discovering, analyzing, and synthesizing compounds through automated in silico experimentation

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034223A (en) 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
WO1992008802A1 (en) 1990-10-29 1992-05-29 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
DK0826695T3 (da) 1996-09-03 2002-04-15 Gsf Forschungszentrum Umwelt Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
EP1077724A2 (en) 1998-04-17 2001-02-28 The University Of Vermont Methods and products related to metabolic interactions in disease
US6217871B1 (en) 1998-10-28 2001-04-17 The Regents Of The University Of California Antigenic epitopes with LYM-1 reactivity and uses thereof
GB0016361D0 (en) 2000-07-03 2000-08-23 Chiron Spa Structure-based HCV drug design
US20020155109A1 (en) 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
JP2005518336A (ja) 2001-06-26 2005-06-23 イムクローン システムズ インコーポレイティド Ｖｅｇｆ受容体に結合する二重特異性抗体
CA2462883A1 (en) 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
CA2463616C (en) 2001-10-15 2011-07-12 Immunomedics, Inc. Affinity enhancement agents
DE10256530A1 (de) * 2002-12-04 2004-06-24 Degussa Ag Verfahren zur Herstellung von wasserfreiem Alkalisulfid
WO2005014618A2 (en) 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005077065A2 (en) 2004-02-09 2005-08-25 The Regents Of The University Of California Selective high-affinity polydentate ligands and methods of making such
WO2006004910A2 (en) 2004-06-28 2006-01-12 Transtarget Inc. Improved bispecific antibodies
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4497432A4 (en) * 2022-03-22 2025-07-30 Bion Inc PROTEIN DELIVERY COMPOSITION CONTAINING BILE SALT AND CATIONIC PEPTIDE AND USE THEREOF

Also Published As

Publication number Publication date
JP5623384B2 (ja) 2014-11-12
US20210000843A1 (en) 2021-01-07
US20180008622A1 (en) 2018-01-11
WO2009132020A2 (en) 2009-10-29
US10874678B2 (en) 2020-12-29
JP2014122234A (ja) 2014-07-03
US20190262364A1 (en) 2019-08-29
AU2009239491B2 (en) 2014-07-17
US11285165B2 (en) 2022-03-29
ES2613844T3 (es) 2017-05-26
CA2721980A1 (en) 2009-10-29
US20180008621A1 (en) 2018-01-11
US10292992B2 (en) 2019-05-21
US20110144065A1 (en) 2011-06-16
US10646502B2 (en) 2020-05-12
CN102083850A (zh) 2011-06-01
CN102083850B (zh) 2015-08-12
EP2268654A2 (en) 2011-01-05
WO2009132020A3 (en) 2009-12-23
JP2011518194A (ja) 2011-06-23
US9884070B2 (en) 2018-02-06
EP2268654B1 (en) 2017-01-25
AU2009239491A1 (en) 2009-10-29
EP2268654A4 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
US11285165B2 (en) Selective high-affinity polydentate ligands and methods of making such
US8536133B2 (en) Selective high-affinity polydentate ligands and methods of making such
JP7133611B2 (ja) 高いインビボ忍容性を有するアントラサイクリン系の抗体薬物複合体
JP2007527391A (ja) 二重特異性抗体の多価キャリヤー
JP2002537362A (ja) ビオチン化ケモカイン抗体複合体
US20220144898A1 (en) Methods and compositions for treating cancer using peptide nucleic acid-based agents
WO2018231661A1 (en) Methods and reagents to treat tumor and cancer
AU2005249553B2 (en) Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
US20210106677A1 (en) Vaccine development methodology based on an adhesion molecule
Wilbur et al. Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants
JPH09501147A (ja) モノアミンオキシダーゼを使用する免疫反応性試薬
JP2022514148A (ja) シンデカン－１および線維芽細胞増殖因子受容体を標的とする二重特異性結合物質
Singh et al. 17 Molecular simulation-based technology for antibody-drug conjugates for tumor
WO2025083185A1 (en) Reducing off-target accumulation of targeted pharmaceutical compounds
JP2023515633A (ja) 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140415

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241023